Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
Patients with locally advanced unresectable or metastatic programmed cell death ligand
(PD-L1) positive triple negative breast cancer (TNBC) will be treated with radiation to
one-four sites of metastasis amenable to radiation (sites of disease to be selected at the
discretion of the treating radiation oncologist) followed by initiation of systemic therapy
with pembrolizumab plus nab-paclitaxel/paclitaxel. Patients will be treated with
pembrolizumab plus nab-paclitaxel/paclitaxel within 7 days of completion of radiation. Repeat
imaging of all sites of disease will be performed every 9 weeks and response will be assessed
according to RECIST 1.1.